Utilizing cell-based therapeutics to overcome immune evasion in hematologic malignancies.
about
Genetically Modified T-Cell-Based Adoptive Immunotherapy in Hematological Malignancies.Limitations and opportunities for immune checkpoint inhibitors in pediatric malignancies.Immunotherapy for the treatment of Hodgkin lymphoma.Treating hematological malignancies with cell therapy: where are we now?Engineering chimeric antigen receptor-T cells for cancer treatment.
P2860
Utilizing cell-based therapeutics to overcome immune evasion in hematologic malignancies.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 20 May 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Utilizing cell-based therapeutics to overcome immune evasion in hematologic malignancies.
@en
Utilizing cell-based therapeutics to overcome immune evasion in hematologic malignancies.
@nl
type
label
Utilizing cell-based therapeutics to overcome immune evasion in hematologic malignancies.
@en
Utilizing cell-based therapeutics to overcome immune evasion in hematologic malignancies.
@nl
prefLabel
Utilizing cell-based therapeutics to overcome immune evasion in hematologic malignancies.
@en
Utilizing cell-based therapeutics to overcome immune evasion in hematologic malignancies.
@nl
P2093
P2860
P1433
P1476
Utilizing cell-based therapeutics to overcome immune evasion in hematologic malignancies.
@en
P2093
Barbara Savoldo
Chuang Sun
Gianpietro Dotti
P2860
P304
P356
10.1182/BLOOD-2015-12-629089
P407
P577
2016-05-20T00:00:00Z